

1 Lawrence H. Stone (SBN 146797)  
 Lindsay L. Ryan (SBN 258130)  
 2 David Z. Feingold (SBN 280194)  
 725 S. Figueroa Street, Suite 2500  
 3 Los Angeles, CA 90017  
 Telephone: (213) 689-0404  
 4 Facsimile: (213) 689-0430  
 stonel@jacksonlewis.com  
 5 lindsay.ryan@jacksonlewis.com  
 david.feingold@jacksonlewis.com

6  
 7 Attorneys for Defendant and Cross-Complainant  
 URIGEN PHARMACEUTICALS, INC.

8 AnnaMary E. Gannon (SBN 92175)  
[amg@dillinghammurphy.com](mailto:amg@dillinghammurphy.com)  
 9 Barbara L. Harris Chiang (SBN 206832)  
[bhc@dillinghammurphy.com](mailto:bhc@dillinghammurphy.com)  
 10 DILLINGHAM & MURPHY LLP  
 601California St., Suite 1900  
 11 San Francisco, CA 94108  
 Telephone: (415) 397-2700  
 12 Facsimile: (415) 397-3300

13 Attorneys for Plaintiff  
 MARTIN E. SHMAGIN

14  
 15 UNITED STATES DISTRICT COURT  
 16 NORTHERN DISTRICT OF CALIFORNIA

18 MARTIN E. SHMAGIN  
 19 Plaintiff,  
 20 v.  
 21 URIGEN PHARMACEUTICALS, INC.  
 22 Defendants.

CASE NO.: 12-cv-2630 JSC  
 Hon. Jacqueline Scott Corley

**JOINT CASE MANAGEMENT  
 CONFERENCE STATEMENT**

Date: August 29, 2013  
 Time: 1:30 p.m.  
 Courtroom: "F"

Complaint Filed: May 22, 2012  
 FAC Filed: June 1, 2012  
 FAC Served: June 15, 2012  
 Trial Date: October 7, 2013

1 URIGEN PHARMACEUTICALS, INC.,

2 Cross-Complainant,

3 v.

4 MARTIN E. SHMAGIN, an Individual;  
5 and DOES 1 through 10, inclusive,  
6 Cross-Defendants.

7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

1 Defendant and Cross-Complainant URIGEN PHARMACEUTICALS, INC.  
2 (“Defendant” or “Cross-Complainant” or “Urigen”) and Plaintiff MARTIN E.  
3 SHMAGIN (“Plaintiff”), by and through their respective counsel of record, hereby  
4 submit the following update in advance of the scheduled Case Management Conference.

5 After extensive negotiations and diligent efforts to finalize the complex settlement  
6 agreement reached in this matter, there remain only two provisions for which the parties  
7 are working to finalize the language. The parties anticipate resolving these issues shortly,  
8 and thereafter executing the Settlement Agreement, however, the agreement will not  
9 likely be executed in time to file a Request for Dismissal in advance of tomorrow’s  
10 hearing. Accordingly, the parties would jointly request that the Court briefly continue the  
11 scheduled Case Management Conference by fourteen (14) days to **September 10, 2013**.

12 Date: August 28, 2013 JACKSON LEWIS, LLP

14 By: /s/ Lawrence H. Stone  
15 Lawrence H. Stone  
16 Lindsay L. Ryan  
17 David Z. Feingold

17 Attorneys for Defendant and Cross-  
18 Complainant  
19 URIGEN PHARMACEUTICALS, INC.

19 Date: August 28, 2013 Dillingham & Murphy, LLP

21 By: /s/ Barbara L. Harris Chiang  
22 AnnaMary E. Gannon  
23 Barbara L. Harris Chiang

24 Attorneys for Plaintiff  
25 MARTIN E. SHMAGIN

25 4844-5925-9925, v. 1 The case management conference is continued to 9/12/13 at 1:30 p.m.

26 Dated: 8/29/2013

